Abstract:The discovery and advances of medicines may be considered as the ultimate relevant translational science effort that adds to human invulnerability and happiness. But advancing a fresh medication is a quite convoluted, costly, and protracted operation, normally costing USD ~2.6 billion and consuming a mean time span of 12 years. Methods to cut back expenditure and hasten new drug discovery have prompted an arduous and compelling brainstorming exercise in the pharmaceutical industry. The engagement of Artificial Intelligence (AI), including the deep-learning (DL) component in particular, has been facilitated by the employment of classified big data, in concert with strikingly reinforced computing prowess and cloud storage, across all fields. AI has energized computer-facilitated drug discovery. An unrestricted espousing of machine learning (ML), especially DL, in many scientific specialties, and the technological refinements in computing hardware and software, in concert with various aspects of the problem, sustain this progress. ML algorithms have been extensively engaged for computer-facilitated drug discovery. DL methods, such as artificial neural networks (ANNs) comprising multiple buried processing layers, have of late seen a resurgence due to their capability to power automatic attribute elicitations from the input data, coupled with their ability to obtain nonlinear input-output pertinencies. Such features of DL methods augment classical ML techniques which bank on human-contrived molecular descriptors. A major part of the early reluctance concerning utility of AI in pharmaceutical discovery has begun to melt, thereby advancing medicinal chemistry. AI, along with modern experimental technical knowledge, is anticipated to invigorate the quest for new and improved pharmaceuticals in an expeditious, economical, and increasingly compelling manner. DL-facilitated methods have just initiated kickstarting for some integral issues in drug discovery. Many technological advances, such as "message-passing paradigms", "spatial-symmetry-preserving networks", "hybrid de novo design", and other ingenious ML exemplars, will definitely come to be pervasively widespread and help dissect many of the biggest, and most intriguing inquiries. Open data allocation and model augmentation will exert a decisive hold during the progress of drug discovery employing AI. This review will address the impending utilizations of AI to refine and bolster the drug discovery operation.

Current Status of Computational Approaches for Small Molecule Drug Discovery

Advances in Computational Structure-Based Drug Design and Application in Drug Discovery.

Past, Present, and Future Perspectives on Computer-Aided Drug Design Methodologies

Computational Methods in Drug Discovery and Development

Current Developments of Computer-Aided Drug Design

Emerging trends in computational approaches for drug discovery in molecular biology

Current perspectives and trend of computer-aided drug design: a review and bibliometric analysis

Computational approaches streamlining drug discovery

Artificial intelligence in drug discovery: recent advances and future perspectives

Deep Machine Learning for Computer-Aided Drug Design

A perspective on the current state-of-the-art of quantum computing for drug discovery applications

Computational Approaches and Drug Discovery: Where Are We Going?

Recent Trends in Drug Design and Discovery

Computer-aided nanodrug discovery: recent progress and future prospects

Computer-Aided Drug Design towards New Psychotropic and Neurological Drugs

Impact of Artificial Intelligence on Compound Discovery, Design, and Synthesis

Artificial Intelligence and Machine Learning Technology Driven Modern Drug Discovery and Development

From Byte to Bench to Bedside: Molecular Dynamics Simulations and Drug Discovery

Recent updates in click and computational chemistry for drug discovery and development

State-of-the-art technology in modern computer-aided drug design

Generative artificial intelligence for small molecule drug design